In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Selank | Mixture Cerebrolysin | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Mixture | |
| Area | Brain and mood | Brain and mood | |
| Evidence | |||
| Amount of evidence | 221 | 1,781 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 8 (7 in people) | 109 (96 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | None registered | 41 · 9 active2 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
No FDA approval and no central EU authorisation (EMA).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Selank | Cerebrolysin |
|---|---|---|
| NeuroprotectionNervous system and cognition | 88 | 66116541086 |
| Cognition and memory |
PepBank is a research reference. Talk to a doctor before you use any peptide.
No FDA approval and no central EU authorisation (EMA).
31130 |
26517293 |
| Exercise and physical functionNervous system and cognition | 22 | 14610343 |
|---|
| Adverse eventsWhole body | 761 | 959041 |
|---|
| Receptor activity and mechanismPharmacology | 4512816 | 2232312377 |
|---|
| Overall treatment effectWhole body | 11 | 3535 |
|---|
| Anxiety and moodNervous system and cognition | 45837 | 261313 |
|---|
| Immune responseImmune and inflammation | 13193 | 3724310 |
|---|
| Inflammation markersImmune and inflammation | 77 | 508366 |
|---|
| PainNervous system and cognition | 22 | 24519 |
|---|
| Brain and neuronal activityNervous system and cognition | 11 | 88 |
|---|
| Oxidative stressLiver | 99 | 2727 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Selank differs from Tuftsin at 3 positions.
What is different
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
No registered trial that tests Selank found in ClinicalTrials.gov.
Top 3 of 41 trials, ranked by phase, then posted results and enrollment: 2 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)
Ever Neuro Pharma GmbH242 participantsOct 2006 to Aug 2007
Vascular Dementia
Ever Neuro Pharma GmbH1,071 participantsSept 2006 to Feb 2011
Ischemic Stroke
Poznan University of Medical Sciences350 participants10 Jan 2023 to est. 31 Mar 2025
Acute Ischemic Stroke
2 more mention it but do not test it. They only measure it or name it in their text.
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Selank | Cerebrolysin |
|---|---|---|
| Overall treatment effectNervous system and cognitionCompared as: value in the arm that got the peptide, in score | No randomized trial result 1 result from other study designs. | 2.84 score CIBIC+ Placebo: 3.68 score Dose studied: 20 mLn = 2422011 |
| Cognition and memoryNervous system and cognitionCompared as: difference from placebo, in p value | No randomized trial result 31 results from other study designs. | 0.02 p value ADAS-Cog comparison p value Dose studied: 30 mL once a day from Monday to Friday4 weeksn = 532000 |
| Vascular functionCardiovascularCompared as: difference from placebo, in unitless | No randomized trial result 4 results from other study designs. | < 0.05 unitless P value for right middle cerebral artery pulsatility index Dose studied: 30 mL daily10 daysn = 462014 |
| Adverse eventsWhole bodyCompared as: share of people in the arm that got the peptide, in % | No randomized trial result 7 results from other study designs. | 85% Treatment completion proportion · Cerebrolysin (G1) Saline (G2): 90% Dose studied: 20 mln = 402016 |
| Exercise and physical functionNervous system and cognitionCompared as: value in the arm that got the peptide, in points | No randomized trial result 2 results from other study designs. | 2.3 points ALSFRS-R change Placebo decrease: 0.9 points Dose studied: 10 mL once daily, five days a week for the first month and three days a week for the next two months1 monthn = 202023 |
| Inflammation markersNervous system and cognitionCompared as: value in the arm that got the peptide, in lesions | No randomized trial result 7 results from other study designs. | 14 lesions Gadolinium-positive lesion count Dose studied: 20 mln = 42016 |
| NeuroprotectionNervous system and cognitionCompared as: difference from placebo, in points | No randomized trial result 8 results from other study designs. | 2.085 points Difference in decreases 10-day cycles over 3 intervalsn not reported2025 |
No randomized trial result
1 result from other study designs.
2.84 score
CIBIC+
Placebo: 3.68 score
Dose studied: 20 mLn = 2422011
No randomized trial result
31 results from other study designs.
0.02 p value
ADAS-Cog comparison p value
Dose studied: 30 mL once a day from Monday to Friday4 weeksn = 532000
No randomized trial result
4 results from other study designs.
< 0.05 unitless
P value for right middle cerebral artery pulsatility index
Dose studied: 30 mL daily10 daysn = 462014
No randomized trial result
7 results from other study designs.
85%
Treatment completion proportion · Cerebrolysin (G1)
Saline (G2): 90%
Dose studied: 20 mln = 402016
No randomized trial result
2 results from other study designs.
2.3 points
ALSFRS-R change
Placebo decrease: 0.9 points
Dose studied: 10 mL once daily, five days a week for the first month and three days a week for the next two months1 monthn = 202023
No randomized trial result
7 results from other study designs.
14 lesions
Gadolinium-positive lesion count
Dose studied: 20 mln = 42016
No randomized trial result
8 results from other study designs.
2.085 points
Difference in decreases
10-day cycles over 3 intervalsn not reported2025